These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34523075)

  • 1. Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
    Labandeira CM; Alonso Losada MG; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz González JM; Gonzalez Palmás MJ; Martínez Miró C; Santos García D
    Adv Ther; 2021 Oct; 38(10):5398-5411. PubMed ID: 34523075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz Gonález JM; Alonso Losada MG; González Palmás MJ; Martínez Miró C
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33801565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study.
    Santos García D; Cabo López I; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Paz González JM; Alonso Losada MG; Gonzalez Palmás MJ; Cores Bartolomé C; Martínez Miró C
    Neurol Sci; 2022 Apr; 43(4):2537-2544. PubMed ID: 34554335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pain Improvement in Parkinson's Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study.
    Santos García D; Yáñez Baña R; Labandeira Guerra C; Cimas Hernando MI; Cabo López I; Paz González JM; Alonso Losada MG; Gonzalez Palmás MJ; Cores Bartolomé C; Martínez Miró C
    J Pers Med; 2021 Aug; 11(8):. PubMed ID: 34442442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.
    Cattaneo C; Müller T; Bonizzoni E; Lazzeri G; Kottakis I; Keywood C
    J Parkinsons Dis; 2017; 7(4):629-634. PubMed ID: 28777756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life and non-motor symptoms in Parkinson's disease patients with subthreshold depression.
    Santos-García D; de Deus Fonticoba T; Suárez Castro E; Aneiros Díaz A; Cores Bartolomé C; Feal Panceiras MJ; Paz González JM; Valdés Aymerich L; García Moreno JM; Blázquez Estrada M; Jesús S; Mir P; Aguilar M; Planellas LL; García Caldentey J; Caballol N; Legarda I; Cabo López I; López Manzanares L; Ávila Rivera MA; Catalán MJ; López Díaz LM; Borrué C; Álvarez Sauco M; Vela L; Cubo E; Martínez Castrillo JC; Sánchez Alonso P; Alonso Losada MG; López Ariztegui N; Gastón I; Pascual-Sedano B; Seijo M; Ruíz Martínez J; Valero C; Kurtis M; González Ardura J; Prieto Jurczynska C; Martinez-Martin P;
    J Neurol Sci; 2020 Nov; 418():117109. PubMed ID: 32927370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease.
    Bianchi MLE; Riboldazzi G; Mauri M; Versino M
    Neurol Sci; 2019 Feb; 40(2):275-279. PubMed ID: 30382437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
    De Masi C; Liguori C; Spanetta M; Fernandes M; Cerroni R; Garasto E; Pierantozzi M; Mercuri NB; Stefani A
    J Neural Transm (Vienna); 2022 Nov; 129(11):1331-1338. PubMed ID: 36070008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
    Cattaneo C; Barone P; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2017; 7(1):95-101. PubMed ID: 27802242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
    Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
    Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease:
    Hattori N; Kogo Y; Koebis M; Ishida T; Suzuki I; Tsuboi Y; Nomoto M
    Front Neurol; 2021; 12():752632. PubMed ID: 35222225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients.
    Stocchi F; Borgohain R; Onofrj M; Schapira AH; Bhatt M; Lucini V; Giuliani R; Anand R;
    Mov Disord; 2012 Jan; 27(1):106-12. PubMed ID: 21913224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.